Showing 153 results
-
Story /A new compound aims to attack dangerous antibiotic-resistant bacteria.
-
Press release /Recommendation based on review of CTL019 r/r B-cell ALL development program, including the pivotal Phase II global ELIANA trial A Biologics License Application (BLA) for this indication is…
-
Press release /– On track to request pre-BLA meeting with FDA in Q2 2018 – – Intends to initiate pivotal trial in SMA Type 1 in Europe and multi-national pre-symptomatic SMA study in the first half of…
-
Ad hoc release /Net sales grew 5% (cc[1], +7% USD) mainly driven by: Cosentyx grew to USD 701 million, (+40% cc) with strong growth in all indications in the US and EU Entresto sales more than doubled to USD…
-
Press release /Approval based on landmark PARADIGMS study showing Gilenya (fingolimod) significantly reduced relapse rates by 82% vs interferon beta-1a; additionally, 85.7% of Gilenya patients were relapse-free…
-
Press release /Novartis leads the way at AAN with 52 abstracts, showcasing its broad portfolio of transformative medicines and innovative solutions for people living with spinal muscular atrophy (SMA), multiple…
-
Press release /Children and adolescents with multiple sclerosis (MS) experience more frequent and often more severe relapses than adults with the disease, hindering their development and ability to take part in…
-
Press release /Treatment with Gilenya (fingolimod) substantially reduced the debilitating impact of MS, with significant decreases in key measures of disease activity vs. interferon beta-1a MS severely affects…
-
Press release /New approval for Gilenya (fingolimod) addresses strong unmet need for younger patients, who often experience more frequent relapses than adults with multiple sclerosis (MS)[1] In a…
-
Press release /With four programs currently in clinical trials and five more expected to enter the clinic by the end of 2016, Novartis has rapidly built a robust portfolio of programs focused on stimulating the…